Actis’ Ashish Singh, Partner and Head of India and SE Asia Real Estate, recently spoke with Kailash Babar at The Economic Times, India about recent real estate investment, Rx Propellant.
“India’s life sciences sector holds huge potential for growth in the current decade, with a large talent pool at significantly competitive cost making it a compelling destination for global R&D and manufacturing,” Ashish Singh told Economic Times.
He believes India is a clear beneficiary of realignment of manufacturing and supply chains as part of de-risking from China when it comes to the life sciences industry.
Rx Propellant, with existing momentum in the business, is looking to be a market leading life science focused real estate developer-operator in India with its long-term alliances in the Indian contract research organizations ecosystem.
The life sciences sector in India is already of global strategic importance, as demonstrated during the Covid-19 pandemic. It is poised for significant growth, owing to a confluence of a number of factors both local and global.
Article published in The Economic Times, 28 June 2022.